--- title: "Protagenic Therapeutics (PTIX) stock and investor profile" url: "https://aibio.space/companies/protagenic-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Protagenic Therapeutics, Inc. (OTC: PTIX), United States. The directory classifies it as Pharmaceuticals: Major." --- PTIX Protagenic Therapeutics, Inc. OTC · United States # Protagenic Therapeutics (PTIX) news Company Updates · 2026-08-20 ## [Protagenic reports FDA pre-IND feedback on PT00114 for generalized anxiety disorder](https://aibio.space/news/protagenic-reports-fda-pre-ind-feedback-pt00114-generalized-anxiety/) The FDA raised no objection to the planned Phase 1 design and identified no clinical hold issues. Protagenic plans to submit the IND before the end of 2026. ## Latest Protagenic Therapeutics news 1. 2026-04-07 Company Updates [Protagenic to end chief financial officer's employment on April 30, 2026](https://aibio.space/news/protagenic-end-chief-financial-officers-employment-april-30-2026/) The board notified Alexander Arrow, MD, on March 31, 2026, that his employment will be terminated effective April 30, 2026. The filing gives no reason for the decision. 2. 2025-08-14 Distress [Protagenic Therapeutics delays 10-Q after approving move to virtual model](https://aibio.space/news/protagenic-therapeutics-delays-10-q-after-approving-move-virtual-model/) Protagenic Therapeutics said on August 14, 2025 that it cannot file its June quarter report on time, because its board approved a restructuring to a virtual operating model on August 8. The company expects to file by August 19, 2025, and the notice gives no cost or cash estimate for the restructuring. 3. 2025-05-19 Mergers [Protagenic Therapeutics combines with Phytanix Bio in all-stock deal](https://aibio.space/news/protagenic-therapeutics-combines-phytanix-bio-all-stock-deal/) Phytanix Bio holders would own about 65% of the combined company before financing, on a fully diluted basis, and their preferred stock and warrants need Nasdaq stockholder approval before they can convert or be exercised. The release's count of six drug candidates includes five preclinical assets. ## Protagenic Therapeutics at a glance - **Ticker**: PTIX - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $565,985 ### Related companies - [Jaguar Health](https://aibio.space/companies/jaguar-health/) NASDAQ: JAGX - [Lexicon Pharmaceuticals](https://aibio.space/companies/lexicon-pharmaceuticals/) NASDAQ: LXRX - [ONCOVISTA INNOVATIVE THERAPIES INC](https://aibio.space/companies/oncovista-innovative-therapies/) OTC: OVIT - [RISING BIOSCIENCES INC](https://aibio.space/companies/rising-biosciences/) OTC: RBII - [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) NASDAQ: CTMX - [Inhibitor Therapeutics](https://aibio.space/companies/inhibitor-therapeutics/) OTC: INTI - [Neumora Therapeutics](https://aibio.space/companies/neumora-therapeutics/) NASDAQ: NMRA - [Kiora Pharmaceuticals](https://aibio.space/companies/kiora-pharmaceuticals/) NASDAQ: KPRX ### Also on OTC - [Allstar Health Brands](https://aibio.space/companies/allstar-health-brands/) ALST - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) MHTX - [Trevena](https://aibio.space/companies/trevena/) TRVN - [Reviva Pharmaceuticals Holdings](https://aibio.space/companies/reviva-pharmaceuticals/) RVPH - [ENCISION INC](https://aibio.space/companies/encision/) ECIA - [Dror Ortho-Design](https://aibio.space/companies/dror-ortho-design/) DROR ## What Protagenic Therapeutics does Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), an endogenous brain signaling peptide. In preclinical animal models, PT00114 has shown efficacy in depression, anxiety, substance abuse and addiction, and PTSD. The company holds exclusive worldwide rights to PT00114 through a license agreement with the University of Toronto. Its first human trial began on September 26, 2023, and the multiple-dose portion of the Phase I study in healthy volunteers has been completed. Protagenic expects to begin a Phase 2 study in late 2026 in a targeted population of patients with chronic stress-related psychiatric disorders. It is also developing follow-on compounds in the TCAP family. Its earlier Phytanix Bio reverse merger was unwound during the year ended March 31, 2026. Programs from that prior business include PHYX-003, an anti-obesity candidate, and PHYX-004, a cannabis-derived extract for bladder pain syndrome and interstitial cystitis, both in preclinical development. | Product or program | What it is | Stage | |---|---|---| | PT00114 | Synthetic TCAP-1 peptide for stress-related neuropsychiatric and mood disorders | Phase I multiple-dose portion completed; Phase 2 expected late 2026 | | PHYX-003 | Anti-obesity candidate from the prior Phytanix Bio business | Preclinical | | PHYX-004 | Cannabis-derived extract for bladder pain syndrome and interstitial cystitis | Preclinical development | Summarised from the company's [10-K filed Aug 14, 2026](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm). ## Protagenic Therapeutics annual financials | Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | [$0](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | | Research and development | [$901,896](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | [$376,740](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | | Net income (loss) | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | [-$3.6 million](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | | Cash from operations | [-$2.8 million](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | [-$1.8 million](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/) | | Cash and equivalents | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1022899/000149315226039221/) | [$14,531](https://www.sec.gov/Archives/edgar/data/1022899/000149315226039221/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $565,985. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Protagenic Therapeutics What is the ticker symbol of Protagenic Therapeutics? Protagenic Therapeutics, Inc. trades under the ticker PTIX on OTC. Where is Protagenic Therapeutics listed? Protagenic Therapeutics, Inc. is listed on OTC. What is the SEC CIK of Protagenic Therapeutics? The SEC Central Index Key (CIK) for Protagenic Therapeutics, Inc. is 1022899. Its filings are on SEC EDGAR. How many shares does Protagenic Therapeutics have outstanding? 1,810,208 shares as of 2026-08-19, per the cover page of its 10-Q filed 2026-08-19. Which country or territory is Protagenic Therapeutics listed under? Our directory records Protagenic Therapeutics, Inc. under United States. What does Protagenic Therapeutics do? Our directory classifies Protagenic Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Protagenic Therapeutics? The ISIN recorded for Protagenic Therapeutics, Inc. is US74365N3017. Does aibio.space cover Protagenic Therapeutics? aibio.space lists Protagenic Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Protagenic Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Protagenic Therapeutics develop? Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), an endogenous brain signaling peptide. What is PT00114 from Protagenic Therapeutics? PT00114: Synthetic TCAP-1 peptide for stress-related neuropsychiatric and mood disorders Stage: Phase I multiple-dose portion completed; Phase 2 expected late 2026. What is PHYX-003 from Protagenic Therapeutics? PHYX-003: Anti-obesity candidate from the prior Phytanix Bio business Stage: Preclinical. What was Protagenic Therapeutics's revenue last year? $0 for the fiscal year ended Mar 31, 2026, as reported to the SEC. Is Protagenic Therapeutics profitable? Protagenic Therapeutics, Inc. reported net income of $1.4 million for the fiscal year ended Mar 31, 2026, and used $2.8 million of cash in operations, per its annual report to the SEC. How much does Protagenic Therapeutics spend on research and development? $901,896 in the fiscal year ended Mar 31, 2026, per its annual report. ## Investor discussion: Protagenic Therapeutics Members talk about Protagenic Therapeutics (PTIX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Protagenic Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm) 2. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038256/formnt10-q.htm) 3. 2026-06-30 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315226031235/formnt10-k.htm) 4. 2026-02-24 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315226007800/form8-k.htm) 5. 2026-02-18 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315226007254/formnt10-q.htm) 6. 2026-01-23 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000135445726000085/xslF25X02/primary_doc.xml) 7. 2026-01-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315226000263/form8-k.htm) 8. 2025-11-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/ex99-1.htm) 9. 2025-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315225023624/formnt10-q.htm) 10. 2025-08-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,4.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225025274/ex99-1.htm) 11. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225024130/formnt10-q.htm) 12. 2025-08-13 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,5.03,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225023588/form8-k.htm) 13. 2025-05-20 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225011633/form8-k.htm) 14. 2025-05-19 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.02,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/ex99-1.htm) 15. 2025-05-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225008455/form8-k.htm) 16. 2025-04-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225006649/ex99-1.htm) 17. 2025-04-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225005368/form8-k.htm) 18. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000164117225001600/form10-k.htm) 19. 2025-03-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315225009597/formdef14a.htm) 20. 2025-02-27 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315225008409/formpre14a.htm) 21. 2025-01-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315225004143/form8-k.htm) 22. 2025-01-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/form8-k.htm) 23. 2024-12-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315224048431/form8-k.htm) 24. 2024-11-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1022899/000149315224047376/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:PTIX on TradingView](https://www.tradingview.com/symbols/OTC-PTIX/). ## SEC filings and registration - **SEC name**: Protagenic Therapeutics, Inc.\new - **CIK**: 1022899 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PTIX (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: March 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 149 FIFTH AVENUE, NEW YORK, NY, 10010 - **Phone**: (212) 994-8200 - **Shares outstanding**: 1,810,208 as of 2026-08-19 (10-Q filed 2026-08-19) - **Former names**: Atrinsic, Inc.; NEW MOTION, INC.; MPLC, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1022899/000149315226039410/form8-k.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1022899/000149315226039221/form10-q.htm) filed 2026-08-19 - [10-K](https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1022899/000149315226015365/form8-k.htm) filed 2026-04-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1022899/000149315226009301/form10-q.htm) filed 2026-03-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1022899/000149315226008605/form8-k.htm) filed 2026-03-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1022899/000149315226007800/form8-k.htm) filed 2026-02-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1022899/000149315226000263/form8-k.htm) filed 2026-01-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001022899), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Protagenic Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker PTIX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Protagenic Therapeutics, Inc. - **Ticker**: PTIX - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US74365N3017 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-PTIX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/protagenic-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Protagenic Therapeutics (PTIX) stock and investor profile", 2026-10-31, https://aibio.space/companies/protagenic-therapeutics/